This week, the ratings of three pharmaceutical stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Allergan, Inc.’s (AGN) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Allergan is a healthcare company focused on developing and commercializing pharmaceuticals, biologics, and medical devices. The stock has a trailing PE Ratio of 35.30. For more information, get Portfolio Grader’s complete analysis of AGN stock.
Acasti Pharma Inc. Class A (ACST) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). The stock gets F’s in Equity, Cash Flow and Sales Growth. To get an in-depth look at ACST, get Portfolio Grader’s complete analysis of ACST stock.
XenoPort, Inc. (XNPT) earns an F this week, falling from last week’s grade of D. XenoPort is a biopharmaceutical company that focuses on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. The stock gets F’s in Earnings Momentum, Equity and Cash Flow. For a full analysis of XNPT stock, visit Portfolio Grader.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.